Analyst Ratings for Viridian Therapeutics
Portfolio Pulse from Benzinga Insights
Viridian Therapeutics (NASDAQ:VRDN) received 8 analyst ratings in the last quarter, with 2 bullish and 6 somewhat bullish, and none bearish. The average 12-month price target is $37.25, with a high of $46.00 and a low of $30.00, representing a 13.37% decrease from the previous target of $43.00. Analysts are specialists who provide ratings and forecasts for stocks, and their opinions are a mix of analysis and personal belief.
December 04, 2023 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Viridian Therapeutics has received mostly positive ratings from analysts, with an average price target of $37.25, which is lower than the previous target of $43.00.
The overall positive ratings from analysts suggest a favorable outlook for VRDN, but the decrease in the average price target may indicate some caution, leading to a neutral short-term impact on the stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100